Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05322954 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder
A Phase 1 study of Substance Use Disorders and Substance-Related Disorders, sponsored by University of Wisconsin, Madison.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05322954: Active Phase 1 study of Substance Use Disorders and Substance-Related Disorders, sponsored by University of Wisconsin, Madison.
NCT05322954 is a Phase 1 study of Substance Use Disorders and Substance-Related Disorders that is active but no longer recruiting, run by University of Wisconsin, Madison. The registered enrollment target is 12 participants, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05322954, a Phase 1 study of Substance Use Disorders and Substance-Related Disorders, is active but no longer recruiting, sponsored by University of Wisconsin, Madison.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of methamphetamine use disorder (MUD). Participants can expect to be actively engaged in the study for up to 26 weeks.
Primary Outcome
Incidence of serious adverse events attributable to psilocybin as categorized according to NCI Common Toxicity Criteria version 4.0. and assigned attribution (probably, possibly, and not related).
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
Wisconsin
- University of Wisconsin - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-03-03 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What the registry record for NCT05322954 still lists
NCT05322954 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 500-participant average among 93 other Substance Use Disorders trials with a reported enrollment target (98% lower).
The record links to 5 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT05322954 reports a single indexed study location in Wisconsin.
Frequently Asked Questions
What is clinical trial NCT05322954 about?
NCT05322954 is a clinical study titled "Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder". The purpose of this research study is to investigate the safety and feasibility of two (2) oral doses of psilocybin when combined with behavioral support for methamphetamine use disorder (MUD). Participants have a diagnosis of methamphetamine use disorder (MUD). Participants can expect to be activel...
What is the current status of trial NCT05322954?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-03-03. Estimated completion is 2026-05.
What conditions does trial NCT05322954 study?
This clinical trial studies the following conditions: Substance Use Disorders, Substance-Related Disorders, Methamphetamine Use Disorder, Stimulant Use Disorder, Chemically-Induced Disorders.
What interventions are being tested in trial NCT05322954?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05322954?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05322954 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance Use Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05322954's enrollment target sits among peer trials
12 90th of 93 higher than 3 of 93 other Substance Use Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance Use Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Supporting Treatment Access and Recovery Through Linkage and Support
RECRUITING · NA
-
Development OF A Novel Peer Recovery Supporter Training Platform
RECRUITING · NA
-
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
RECRUITING · NA
-
Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts
RECRUITING · NA
-
Families Left Behind
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI